NeoGenomics, Inc. (NEO)

Time to buy NEO?

8.05

+0.21

+(2.74%)

As of 10:30:28 AM EDT. Market Open.

Time to buy NEO?

NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

NeoGenomics ( NASDAQ:NEO ) First Quarter 2025 Results Key Financial Results Revenue: US$168.0m (up 7.5% from 1Q 2024...

Simply Wall St. 19 hours ago

NEO
+2.74%
3 Small-Cap Stocks Walking a Fine Line

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

StockStory yesterday

SPT

ACHC

NEO
+2.74%
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who sees “more questions than answers” following the company’s quarterly report. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analys

TipRanks 4 days ago

NEO
+2.74%
NeoGenomics Pays Off 1.25% Convertible Senior Notes

FORT MYERS, Fla., May 01, 2025--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.

Business Wire 5 days ago

NEO
+2.74%
NeoGenomics Inc (NEO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

NeoGenomics Inc (NEO) reports an 8% revenue increase and strategic advancements, despite challenges in the non-clinical sector.

GuruFocus.com 6 days ago

NEO
+2.74%
Why NeoGenomics (NEO) Stock Is Nosediving

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-ye

StockStory 6 days ago

NEO
+2.74%
NeoGenomics (NEO) Reports Break-Even Earnings for Q1

NeoGenomics (NEO) delivered earnings and revenue surprises of 100% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

NEO
+2.74%
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation cent

PR Newswire 7 days ago

NEO
+2.74%
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.

StockStory 7 days ago

NEO
+2.74%
NeoGenomics: Q1 Earnings Snapshot

NEO) on Tuesday reported a loss of $25.9 million in its first quarter. The Fort Myers, Florida-based company said it had a loss of 20 cents per share. Earnings, adjusted for stock option expense and amortization costs, were less than 1 cent on a per-share basis.

Associated Press Finance 7 days ago

NEO
+2.74%
NeoGenomics Reports First Quarter 2025 Results

FORT MYERS, Fla., April 29, 2025--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

Business Wire 7 days ago

NEO
+2.74%
NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what investors should know.

StockStory 8 days ago

NEO
+2.74%
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 13 days ago

NEO
+2.74%

GSK
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 14 days ago

NEO
+2.74%

CELG-RT
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

FORT MYERS, Fla., April 22, 2025--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.

Business Wire 14 days ago

NEO
+2.74%
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

FORT MYERS, Fla., April 08, 2025--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.

Business Wire 28 days ago

NEO
+2.74%
NeoGenomics Completes Acquisition of Pathline

FORT MYERS, Fla., April 07, 2025--NeoGenomics has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

Business Wire 29 days ago

NEO
+2.74%
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.

StockStory last month

NEO
+2.74%

RDNT

LH
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

FT. MYERS, Fla., April 01, 2025--NeoGenomics announced that Tony Zook has officially assumed the role of Chief Executive Officer.

Business Wire last month

NEO
+2.74%
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack

Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.

StockStory last month

LH

RDNT

NEO
+2.74%

Performance Overview

Return	NEO	S&P 500 (^GSPC)
YTD	-51.12%	-4.40%
1-Year	-48.07%	+8.53%
3-Year	-15.30%	+36.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

NeoGenomics, Inc. (NEO)

NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Small-Cap Stocks Walking a Fine Line

NeoGenomics price target lowered to $10 from $17 at Morgan Stanley

NeoGenomics Pays Off 1.25% Convertible Senior Notes

NeoGenomics Inc (NEO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Why NeoGenomics (NEO) Stock Is Nosediving

NeoGenomics (NEO) Reports Break-Even Earnings for Q1

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops

NeoGenomics: Q1 Earnings Snapshot

NeoGenomics Reports First Quarter 2025 Results

NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

NeoGenomics Completes Acquisition of Pathline

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack

Performance Overview